Actuate Therapeutics Announces Initiation of a Multicenter
Elraglusib will be combined with FOLFIRINOX alone or with Losartan in multi-center Phase 2 clinical study initiated at Massachusetts General Hospital, Fred...
United States Dana Farber Cancer Institute Colind Weekes Andrew Rakeman Daniel Schmitt Johns Hopkins University
Source: globenewswire.com